Table 3. Effectiveness of the perindopril shown for the subgroup of the study cohort with previously diagnosed hypertension. * significant difference from previous visit, p < 0.001 .
| Baseline (n=801) |
Visit 1 (3 months from the baseline) (n=796) |
Visit 2 (6 months from the baseline) (n=787) |
Visit 3 (9 months from the baseline) (n=771) |
Δbaseline-Visit 3 | |
|---|---|---|---|---|---|
| Systolic blood pressure (mmHg) | 161.0±14.3 | 145.8±27.6* | 136.4±10.8* | 132.0±9.0* | 29.1±14.8* |
| Diastolic blood pressure (mmHg) | 97.1±16.2 | 87.2±8.3* | 83.4±30.1* | 79.7±6.9* | 17.6±26.8* |
| Percent of patients achieving systolic normotension (<140 mmHg) | 0% | 184 (23.1%) | 416 (52.9%) | 570 (73.9%) | 73.9% |
| Percent of patients achieving diastolic normotension (<90 mmHg) | 0% | 373 (46.9%) | 595 (75.6%) | 690 (89.5%) | 89.5% |
| Percent of patients achieving both systolic and diastolic normotension (<140/90 mmHg) | 0% | 158 (19.8%) | 395 (50.2%) | 556 (72.1%) | 72.1% |
| Percent of patients with reduction of systolic pressure ≥10 mmHg | 0% | 639 (80.3%) | 724 (92.0%) | 731 (94.8%) | 94.8% |
| Percent of patients with reduction of diastolic pressure ≥5 mmHg | 0% | 599 (75.3%) | 689 (87.5%) | 712 (92.3%) | 92.3% |